Darnatein’s therapeutic focus centers on creating next-generation Bone Morphogenetic Proteins (BMPs), essential regulators of bone and cartilage repair. By engineering more potent, lower-dose BMP therapeutics, we aim to directly address the biological drivers of age-related degenerative diseases.

Osteoarthritis

Preclinical data indicate that DRT-101 has the potential to become a first-in-class, disease-modifying osteoarthritis drug (DMOAD). 

By restoring joint biology rather than merely treating symptoms, DRT-101 could redefine the standard of care for osteoarthritis. Its intra-articular dosing approach offers a more accessible, lower-cost alternative to chronic supportive care and, ultimately, major endoprosthetic surgery—delivering meaningful benefits to both patients and healthcare systems.

Spinal Fusion

DRT-102 is designed for broad applicability across conditions characterized by impaired bone healing. Its enhanced regenerative activity positions it for clinical use in non-union fractures, spinal fusion, orthopedic trauma, and dental implantology, offering a versatile treatment option where improved bone formation is needed.